In this issue of JAMA Internal Medicine, Feldman and colleagues¹ report that Medicare spending on insulin for patients with diabetes was an estimated $7.8 billion, which is $4.4 billion more than the Centers for Medicare & Medicaid Services might have spent by using the prices negotiated by the US Department of Veterans Affairs and their formulary restrictions. Even if the $4.4 billion figure overestimates the potential savings, the potential for lower prices would substantially increase many patients’ access to life-saving insulin products.

中文翻译：

---

减少处方药上的医疗保险支出。

在本期《JAMA内科医学》中，Feldman及其同事¹报告称，Medicare在糖尿病患者胰岛素上的支出估计为78亿美元，比Medicare＆Medicaid Services中心通过使用美国退伍军人事务部及其配方限制。即使44亿美元的数字高估了潜在的节省，降低价格的潜力也将大大增加许多患者获得挽救生命的胰岛素产品的机会。